$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

$SAVA , VERA announced positive phase 2b results meeting primary end point.

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients

Clinical stages and jumps 286% up to $9.76 from $1.77.

The market learned excellent news about NWBO: its key drug had met both its primary and secondary endpoints in its GBM clinical trial with excellent news that should have caused NWBO’s share price to increase, absent manipulation in the market.

$RIDE wow this consolidaiton phase is massive.

Its great we are in production phase of the endurance to FLEETs,

Anyway, since this trial is expensive and yet necessary for regulatory approval; I interpret it as a bullish signal.

2023 is going to be highlighted with a continuous cascade of amazingly positive PR’s confirming the fact (already documented in 300+ early clinical studies), that Rencofilstat is truly a Wonder Drug to be celebrated, with an extraordinarily large TAM.

$HEPA Was hoping we would get an update on our (Nash) trial soon and we got this surprising good news.

I didnt sell a share and with stellar results for this soon to be released study it should gain traction well over 3 imo.

We knows recession is coming next year 4) XBI has bottomed and should begin its upward move next year 5) Phase 2b trial results and updates on HCC trial 6) Probable approvals of NASH drugs and increased bullish sentiment in the sector

Sign up for the free trial, it's easy.

button for good trial results in the NASH space.

Highly statistically significant results because of the large trial size.